JP2024539930A5 - - Google Patents

Info

Publication number
JP2024539930A5
JP2024539930A5 JP2024524412A JP2024524412A JP2024539930A5 JP 2024539930 A5 JP2024539930 A5 JP 2024539930A5 JP 2024524412 A JP2024524412 A JP 2024524412A JP 2024524412 A JP2024524412 A JP 2024524412A JP 2024539930 A5 JP2024539930 A5 JP 2024539930A5
Authority
JP
Japan
Prior art keywords
day
approximately
less
pharmaceutical composition
asbti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024524412A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539930A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/047719 external-priority patent/WO2023076260A1/en
Publication of JP2024539930A publication Critical patent/JP2024539930A/ja
Publication of JP2024539930A5 publication Critical patent/JP2024539930A5/ja
Pending legal-status Critical Current

Links

JP2024524412A 2021-10-26 2022-10-25 頂端側ナトリウム依存性輸送体阻害剤組成物 Pending JP2024539930A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163271857P 2021-10-26 2021-10-26
US63/271,857 2021-10-26
PCT/US2022/047719 WO2023076260A1 (en) 2021-10-26 2022-10-25 Apical sodium-dependent transporter inhibitor compositions

Publications (2)

Publication Number Publication Date
JP2024539930A JP2024539930A (ja) 2024-10-31
JP2024539930A5 true JP2024539930A5 (https=) 2025-10-23

Family

ID=86158469

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024524412A Pending JP2024539930A (ja) 2021-10-26 2022-10-25 頂端側ナトリウム依存性輸送体阻害剤組成物

Country Status (15)

Country Link
US (1) US20230181527A1 (https=)
EP (1) EP4422632A4 (https=)
JP (1) JP2024539930A (https=)
KR (1) KR20240089019A (https=)
CN (1) CN118159270A (https=)
AR (1) AR127467A1 (https=)
AU (1) AU2022376147A1 (https=)
CA (1) CA3232317A1 (https=)
CL (1) CL2024001247A1 (https=)
CO (1) CO2024005059A2 (https=)
IL (1) IL311482A (https=)
MA (1) MA65143A1 (https=)
MX (1) MX2024004916A (https=)
TW (1) TW202333722A (https=)
WO (1) WO2023076260A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3923943B1 (en) 2019-02-12 2024-07-31 Mirum Pharmaceuticals, Inc. Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
US20250345326A1 (en) * 2024-05-07 2025-11-13 Mirum Pharmaceuticals, Inc Methods for treating cholestatic pruritus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2552657T3 (es) * 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
AU2012328526B2 (en) * 2011-10-28 2017-05-25 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
EP3923943B1 (en) * 2019-02-12 2024-07-31 Mirum Pharmaceuticals, Inc. Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency

Similar Documents

Publication Publication Date Title
US12599602B2 (en) Methods for treating cholestasis
US20230138455A1 (en) METHODS OF DOSING OF APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITORS (ASBTIs)
JP2024539930A5 (https=)
US20230181527A1 (en) Apical sodium-dependent transporter inhibitor compositions
RU2829466C2 (ru) Способы лечения холестаза
HK40112462A (zh) 顶端钠依赖型转运蛋白抑制剂组合物
HK40112370A (zh) 顶端钠依赖型胆酸转运蛋白抑制剂(asbti)的给药方法
HK40065061B (en) Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
HK40065061A (en) Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
HK40065058B (en) Methods for increasing growth in pediatric subjects having cholestatic liver disease
HK40065058A (en) Methods for increasing growth in pediatric subjects having cholestatic liver disease